Sensorion reported disappointing results in a Phase 2 trial of SENS-111 for the treatment of acute unilateral vestibulopathy (AUV). It now plans to focus its efforts on its SENS-401 drug designed to treat sudden sensorineural hearing loss (SSNHL).